<DOC>
	<DOCNO>NCT00698685</DOCNO>
	<brief_summary>This study test hypothesis purely immunosuppressive preparative regimen allow engraftment relate unrelated allogeneic hematopoietic stem cell subject high-risk malignancy , without cause post-transplant myelosuppression ( e.g. , neutropenia , thrombocytopenia ) occur currently use reduced-intensity ( nonmyeloablative ) preparative regimen . This study incorporate safety efficacy endpoint evaluate novel preparative regimen alemtuzumab plus continuous-infusion pentostatin , two immunosuppressive agent different mechanism action , recipient relate unrelated allogeneic hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Pentostatin Alemtuzumab Preparative Regimen Allogeneic Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>Primary Objectives study : - To determine efficacy preparative regimen pentostatin alemtuzumab plus related unrelated allogeneic peripheral blood stem cell transplantation ( PBSCT ) induce durable donor lymphohematopoietic cell chimerism ( define least 50 % donor cell peripheral blood ) 100 day PBSCT ( day +100 ) subject high-risk malignancy high risk morbidity mortality conventional intensive pre-transplant conditioning regimen . - To determine safety preparative regimen pentostatin alemtuzumab plus related unrelated allogeneic PBSCT , measure non-relapse mortality day +100 study subject population .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>One diagnose : Acute myeloid leukemia complete partial remission Acute lymphocytic leukemia complete partial remission Chronic myeloid leukemia first subsequent chronic phase accelerate phase Chronic lymphocytic leukemia recur fail least one course frontline therapy Hodgkin 's disease nonHodgkin 's lymphoma fail frontline therapy , second subsequent remission , chemosensitive relapse Multiple myeloma complete partial remission chemosensitive relapse Myelodysplastic Syndrome classify intermediate2 high risk accord International Prognostic Scoring System Metastatic renal cell carcinoma fail least one previous frontline chemotherapy and/or biological therapy regimen radiographically detectable evaluable Treatment least one previous course chemotherapy biological therapy malignancy allogeneic PBPCT consider ( i.e. , subject enrol study initial treatment malignancy ) . AND least one following : Age 50 year old . Previous transplant autologous allogeneic hematopoietic cell ( peripheral blood , bone marrow , placental blood ) . Highrisk status hematologic malignancy , i.e. , first complete remission first chronic phase . Presence medical condition could place subject unacceptably high risk regimenrelated mortality document chronic bronchitis emphysema ; decrease cardiac ejection fraction ( ejection fraction least 30 % ) , history coronary artery disease ; renal insufficiency ( creatinine clearance least 30 mL/min ) ; hepatic cirrhosis ( normal hepatic synthetic function ) ; document presume invasive fungal infection require treatment intravenous antifungal agent ( ) . Eligibility another clinical therapeutic protocol standardofcare treatment offer high probability cure longterm control subject 's malignancy . Progressive Hodgkin 's disease , nonHodgkin 's lymphoma , Hodgkin disease multiple myeloma refractory salvage chemotherapy . Acute leukemia ( AML ALL ) relapse , CML blast phase/blast crisis , MDS great 30 % marrow involvement ( MDSAML ) . Subjects disease characteristic may consider study complete partial remission ( CRs PRs ) occur salvage chemotherapy . Severe organ dysfunction , : cardiac ejection fraction 30 % symptomatic ischemic cardiac disease ; creatinine clearance 30 mL/min ; carbon monoxide diffuse capacity ( DLCO ) 35 % and/or need supplemental oxygen ; severe hepatic cirrhosis ascites and/or varix ; hepatic dysfunction associate abnormal synthetic function ( e.g. , coagulopathy ) and/or bilirubin great two time upper limit normal and/or transaminase ( AST ALT ) four time upper limit normal . Untreated progressive central nervous system involvement malignancy Subject pregnant breastfeeding . Karnofsky score 50 Seropositivity human immunodeficiency virus ( HIV ) . Life expectancy le 12 week conventional treatment . For subject fertile , refusal practice contraception upon enter study least 12 month PBPCT cessation immunosuppressive treatment ( e.g. , cyclosporine ) , whichever occurs later . Failure obtain least 5.0 x 106 allogeneic donor CD34+ cell per kg recipient weight PBPC product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
	<keyword>Preparative Regimen</keyword>
	<keyword>Pentostatin</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Hodgkin Disease Lymphoma , non-Hodgkin</keyword>
	<keyword>leukemia , myeloid , acute</keyword>
	<keyword>leukemia , lymphocytic , acute</keyword>
	<keyword>leukemia , myeloid , chronic</keyword>
	<keyword>leukemia , lymphocytic , chronic</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Carcinoma , Renal Cell</keyword>
</DOC>